News

News

Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.

10.03.2014

AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.

LinkedIn1Twitter1Facebook0Google+0tumblr

Comments are closed.

EMA: Draft guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products
EMA: Facilitating the development of gene therapies
FDA cautions about dose confusion and medication errors for antibacterial drug Zerbaxa (ceftolozane and tazobactam)
FDA: Breakthrough Therapy Designation: An Analysis of the Past Two and a Half Years
ANSM: Avis et recommandations du Comité des médicaments orphelins (COMP) de l’Agence européenne des médicaments (EMA) d’avril 2015
ANSM: Avis et recommandations du Comité des médicaments pédiatriques (PDCO) de l’Agence européenne des médicaments (EMA) d’avril 2015
FDA Draft Guidance on Adaptive Design for Medical Device Clinical Studies
FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood
FDA Guidance for Industry: Biosimilars – Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
FDA: Draft Guidance on Patient Preference Information – Submission, Review in PMAs, HDE Applications, and De Novo Requests, and Inclusion in Device Labeling